Location Directory

Clinical trials in Aurora, Colorado

This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7434

Shown on this page

Local exact-city summaries

1958

Based on exact city/state matches in the local index.

Local exact-city recruiting

988

Live official results below use the broader ClinicalTrials.gov location search.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Showing 1–12 of 7,434 matching trials in Aurora, CO.

Live ClinicalTrials.gov results.

The summary panels count exact city/state matches in the stored directory for Aurora, CO. The trial list uses ClinicalTrials.gov location matching when live results are available, which can differ from those local counts. No distance radius is applied; check each official record for its listed facilities. During an upstream outage, the list may use the clearly labeled local fallback.

Top conditions in local exact-city summaries

Breast Cancer 45 Obesity 28 Colorectal Cancer 21 Malignant Solid Neoplasm 21 Heart Failure 18 Type 1 Diabetes 18

Top sponsors in local exact-city summaries

University of Colorado, Denver 293 National Cancer Institute (NCI) 184 Children's Oncology Group 49 AstraZeneca 44 Merck Sharp & Dohme LLC 41 VA Office of Research and Development 39

Top therapies in local exact-city summaries

Pembrolizumab 77 Carboplatin 69 Nivolumab 58 Paclitaxel 58 Cyclophosphamide 53 Cisplatin 46

Institutions in Aurora

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

University of Colorado Anschutz

Live official records

Open in full search

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions: zagociguat 15mg; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Interventions: Adagrasib, Pembrolizumab; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 220
States / cities: Goodyear, Arizona • Prescott Valley, Arizona • Safford, Arizona + 168 more

Conditions: Non-small Cell Lung Cancer
Interventions: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 26
States / cities: Sacramento, California • Aurora, Colorado • New Haven, Connecticut + 22 more

Conditions: Cytomegalovirus Prophylaxis
Interventions: Letermovir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more

Conditions: High-Risk Neuroblastoma
Interventions: hu1418K322A + Temozolomide + Irinotecan; Drug
Lead sponsor: Renaissance Pharma Ltd.; Industry
Eligibility: 18 Months to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Interventions: No Intervention; Other
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 100 more

Conditions: Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 6 Years and older · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more

Conditions: Eosinophilic Esophagitis
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Atypical Hemolytic Uremic Syndrome
Interventions: Crovalimab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Parkinson's Disease (PD)
Interventions: adaptive DBS (aDBS); Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Clinical trials in Aurora, Colorado

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Institutions in Aurora

Live official records

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Defining Endpoints in Becker Muscular Dystrophy

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease